CalciMedica, Inc. · NASDAQ:CALC

CalciMedica — Merger or Acquisition (November 2022)

23 slides from CalciMedica's merger presentation, Nov 22, 2022

  1. Slide 1: Merger Announcement

    Merger Announcement November 22, 2022 1

  2. Slide 2: Disclaimers

    Disclaimers For the purposes of this notice, the “presentation” that follows shall mean and include the slides that follow, the oral presentation of the slides by members of management of Graybug Vision, Inc. (“Graybug”) and CalciMedica, Inc. (“CalciMedica”) or any person on their behalf, any questi

  3. Slide 3: Merger to create Nasdaq-listed clinical-stage biopharmaceutical company

    Merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on developing first-in-class therapies for life-threatening inflammatory diseases CalciMedica Provides Graybug shareholders with opportunity to participate in company with strong clinical-stage Opportunity pipeline and

  4. Slide 4: Transaction Summary

    Transaction Summary • Combined company expected to trade on Nasdaq Global Market Ownership • Expected ownership ~71% CalciMedica, ~29% Graybug, subject to adjustment based on Graybug’s net cash at closing • Existing CalciMedica management to lead combined company Management • Board of Directors will

  5. Slide 5: CalciMedica is Building a Leading Company Dedicated to Treating Life-threatening Inflammatory Diseases

    CalciMedica is Building a Leading Company Dedicated to Treating Life-threatening Inflammatory Diseases Proprietary technology targeting CRAC channel inhibition to develop Differentiated first-in-class therapies for life-threatening inflammatory diseases with high Technology unmet need Compelling Aux

  6. Slide 6: Activation of CRAC Channels Leads to Immune System Activation

    Activation of CRAC Channels Leads to Immune System Activation; Overactivation Can Result in Cell Injury or Death in Multiple Organs Ca2+ • Toxins CRAC channel • Infection overactivation • Trauma Calcium excess in the cytoplasm Immune/ • Leads to tissue cell injury T-Cell • Activates immune system ce

  7. Slide 7: Auxora Has Demonstrated Biological Activity and Favorable Safety Profile in Phase 2 Trials

    Auxora Has Demonstrated Biological Activity and Favorable Safety Profile in Two Ongoing and Four Completed Phase 2 Trials Population Trial Size Results Pancreas Asparaginase-Associated N=9 • Trial ongoing, preliminary results show rapid resolution of pain and food tolerance Pancreatitis Acute Pancre

  8. Slide 8: Auxora Pipeline Addressing Significant Unmet Patient Needs

    Auxora Pipeline Addressing Significant Unmet Patient Needs Near-Term Readouts for Auxora in Development for Pancreas Phase of Development Program* Indication Anticipated Milestones Preclinical Phase 1 Phase 2 Phase 3 Pancreas CARPO Phase 2b Trial Ongoing Auxora Acute Pancreatitis Data in 2H23 Aspara

  9. Slide 9: Market Opportunity for Auxora Across Acute Inflammatory Diseases with High Unmet Need

    Market Opportunity for Auxora Across Acute Inflammatory Diseases with High Unmet Need AP with SIRS AAP Moderate to Severe AKI ~100K ~300 ~1.1M Patients Patients Patients • No approved therapies • No approved therapies • No approved therapies • SOC primarily supportive care • Ultra-orphan pediatric i

  10. Slide 10: Auxora for Acute Pancreatitis

    Auxora for Acute Pancreatitis 10

  11. Slide 11: Significant Unmet Need in Treatment of Acute Pancreatitis

    Significant Unmet Need in Treatment of Acute Pancreatitis U.S. Hospitalizations per Year From Acute Pancreatitis: ~275,000 ~40% of patients present with SIRS High risk for moderate to severe disease Patients with SIRS+: ~110,000 Small percentage of patients missed Misdiagnosis, timing constraint, or

  12. Slide 12: Auxora has the Potential to Offer Significant Clinical Benefits to Patients with Predicted Severe AP

    Auxora has the Potential to Offer Significant Clinical Benefits to Patients with Predicted Severe AP 1. Fluid resuscitation Current standard of care is 2. Enteral nutrition for food tolerance limited to supportive therapy 3. Antibiotics for infection 4. Minimally invasive therapy for local complicat

  13. Slide 13: Auxora Phase 2a Trial in Acute Pancreatitis

    Auxora Phase 2a Trial in Acute Pancreatitis Exploring Safety, Tolerability and Efficacy Compared to Standard of Care Dose Escalation Auxora Low dose (n=8) N=21 Day 1: 1.0 mg/kg IV Days 2-4: 1.4 mg/kg IV High dose (n=6) Screening Days 1 and 2: 2.08 mg/kg IV • Assess for SIRS 2:1 Days 3 and 4: 1.60 mg

  14. Slide 14: Auxora Positive Phase 2a Results on all Primary Endpoints

    Auxora Positive Phase 2a Results on all Primary Endpoints Rapid Increase in Patients Tolerating Solid Diet >2 Fewer Days Spent in Hospital Potential Pivotal Trial Primary Endpoint Median Hospital Stay 100 93% SOC patients (n=7) 6.0 days % of Patients Tolerating Solid Diet 90 80 Auxora-treated patien

  15. Slide 15: Auxora Phase 2b Trial (CARPO) in Acute Pancreatitis

    Auxora Phase 2b Trial (CARPO) in Acute Pancreatitis Ongoing, with Data Expected 2H23 Primary Endpoint Secondary Endpoints • Time to solid food tolerance • Time to medically indicated discharge • Length of stay at the hospital or ICU • Re-hospitalization rates • Development of pancreatic necrosis N=2

  16. Slide 16: Potential to Offer Significant Clinical Benefits to Children with AAP

    Potential to Offer Significant Clinical Benefits to Children with AAP 3,000+ 7-10% 50%+ children with acute of ALL patients develop of patients with AAP lymphoblastic leukemia asparaginase-associated develop pseudocyst or (ALL) treated with pancreatitis (AAP) as a pancreatic necrosis, chemotherapeut

  17. Slide 17: Proof-of-Concept Ongoing in AAP

    Proof-of-Concept Ongoing in AAP Pediatric Patients Receiving Auxora Had Rapid Resolution of Food Tolerance and Pain • CRSPA Phase 1/2 Trial in pediatric Asparaginase-Associated Pancreatitis (AAP) – Investigator-initiated, open-label trial • Trial Status – Assess the safety in pediatric patients with

  18. Slide 18: Supporting Data in COVID-19 Pneumonia Patients

    Supporting Data in COVID-19 Pneumonia Patients 18

  19. Slide 19: CARDEA Phase 2 Trial Showed 40% Reduction in Reported Acute Kidney Injury

    CARDEA Phase 2 Trial Showed 40% Reduction in Reported Acute Kidney Injury in COVID-19 Pneumonia Patients Ang-2/Tie2 results in endothelial inflammation Ang-1/Tie2 signaling maintains vascular integrity with resulting endothelial cell activation and increased endothelial permeability Angiopoietin-1 L

  20. Slide 20: CARDEA Phase 2 Showed Reduction in Mortality and Ventilator Use in COVID-19 Pneumonia Patients

    CARDEA Phase 2 Showed Reduction in Mortality and Ventilator Use in COVID-19 Pneumonia Patients 56% Relative Risk Reduction 33% Relative Risk Reduction in Mortality at Day 30 (p=0.023) in Ventilator Use at Day 60 (p=0.18) Ventilated Patients Placebo 27.5% Auxora-treated patients 18.5% >2 Fewer Days S

  21. Slide 21: Anticipated Milestones

    CalciMedica The CRAC Channel Company Anticipated Milestones

  22. Slide 22: Cash at Close Expected to Provide Runway into 2H24 Funding Key Clinical Milestones

    Cash at Close Expected to Provide Runway into 2H24 Funding Key Clinical Milestones 1H23 2H23 1H24 Phase 2b Data End of Phase 2 Acute Pancreatitis Expected FDA Meeting Expected Asparaginase-Associated Initial Phase 1/2 Pancreatitis Data Expected FDA Meeting Anticipated AAP: Asparaginase-associated pa

  23. Slide 23: CalciMedica is Building a Leading Company Dedicated to Treating Life-threatening Inflammatory Diseases

    CalciMedica is Building a Leading Company Dedicated to Treating Life-threatening Inflammatory Diseases Leader in CRAC Pipeline to Address Multiple Near-Term Strong Financial Channel High Unmet Milestones in 2023 Position and Inhibition Medical Need Management Team 23

CalciMedica — Merger or Acquisition (November 2022) on 6ix